XML 22 R12.htm IDEA: XBRL DOCUMENT
v3.21.2

INVESTMENT IN ASSOCIATE | 3 Months Ended
--- | ---
Jun. 30, 2021
Investment In Associate |
INVESTMENT IN ASSOCIATE | NOTE 7. INVESTMENT IN ASSOCIATE Details of the Company’s associate as of June 30, 2021 and March 31, 2021 are as follows:
Schedule of investment associate |  |  |  |  |  |  |  |
Name |  | Principal Activity |  | Place of Incorporation and Principal Place of Business |  | Voting Rights Held as of June 30, 2021 |  | Voting Rights Held as of March 31, 2021
Associate: Stimunity S.A. |  | Biotechnology |  | Paris, France |  | 44.0% |  | 44.0%
The abovementioned associate is accounted for using the equity method in these condensed consolidated interim financial statements. The following table is a roll-forward of the Company’s investment in Stimunity S.A. as of June 30, 2021 and 2020:
Schedule of investment in Stimunity S.A. |  |  |  |
|  | Three Months Ended June 30,
(In thousands) |  | 2021 |  | 2020
Balance, beginning of period |  | $ | 1,735 |  |  | $ | 1,225 |
Additional investment |  |  | – |  |  |  | 1,000 |
Share of (loss) income |  |  | (44 | ) |  |  | 440 |
Balance, end of period |  | $ | 1,691 |  |  | $ | 2,665 |
On June 1, 2020, the Company made an additional $1.0 million investment in Stimunity upon Stimunity's achievement of certain agreed milestones, increasing its equity share in Stimunity to 44% (see Note 17, “Commitments and Contingent Liabilities”). The Company accounts for its investment in Stimunity under the equity method and accordingly, records its share of Stimunity’s earnings or loss based on its ownership percentage. The Company recorded equity in (loss) income in Stimunity of ($44,000) and $440,000 for the three months ended June 30, 2021 and 2020, respectively. Under the shareholders agreement, Portage has (i) a preferential subscription right to maintain its equity interest in Stimunity in the event of a capital increase from the issuance of new securities by Stimunity, except for issuances of new securities for stock options under a merger plan or for an acquisition, or (ii) the right to vote against any (a) issuances of additional securities that would call for the Company to waive its preferential subscription right, or (b) any dilutive issuance.

X
- References No definition available. + Details
Name: | ptgef_DisclosureInvestmentInAssociateAbstract
Namespace Prefix: | ptgef_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ptgef_InvestmentInAssociateDisclosureTextBlock
Namespace Prefix: | ptgef_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration